i think obese people will want to get skinny i think health is something people care about and obsessed over i think more singles will live longer than married couples i think we will get lesser babies overtime.

Verdict: a disciplined watch-list waiting on HCAT — not a buy today

The honest verdict is that this is a watch-list, not a trade. The strongest point in its favor is that the rules impose real discipline: a long entry only when a name taps support and closes above it, with a fixed 2% stop against a 4% target, and HCAT sits just 1% above its $1.70 trigger with net insider buying of roughly $105,000 across three filers in the June 30, 2026 report. The strongest point against is that four of the five tickers — a bank (LOB), a concert promoter (LYV), a media company (PPLI), and a holding company (LIVE) — have no plausible connection to the obesity, health, singles, and fertility thesis, and the one genuinely thematic name, HCAT, just swung to negative free cash flow of $70,000 in the June 2026 quarter from positive $18.2 million the quarter before with a negative 51.8% operating margin. What would flip the verdict: a demonstrated link between the demographic narrative and a ticker's fundamentals — most plausibly HCAT returning to positive free cash flow in the Q3 filing (period ending September 30, 2026) while printing a support tap and close above $1.70. Note that LIVE's fundamentals date to fiscal Q4 2022, a delayed disclosure, not a current picture. Until one of those support taps confirms, wait.

Trade now: a support-tap watch list, not a trade

There is nothing to buy today. This setup only allows a long entry when a ticker's daily low touches its first support level and the daily close finishes above that same level. Right now all five names sit above their triggers, so the rules were evaluated on live bars and none fired — this is a watch-list posture by design, not an active signal. **HCAT is closest to triggering.** It closed at $1.72 with first support at $1.70, so roughly a 1% dip followed by a close back above $1.70 would arm the entry. LIVE is next, trading at $7.85 against $7.80 support (about 0.6% away). PPLI sits at $39.54 against $39.42 support (about 0.3%), LYV at $172.45 against $170 support (about 1.4%). LOB is the outlier: its listed first support of $37.47 is above the $37.15 close, so the entry condition as written is not coherent for that name and should be treated as inactive until price reorients. Once an entry arms, the position rules are mechanical: a 2% stop loss and a 4% take profit, plus a resistance-based target at the nearest resistance band (HCAT at $1.80, LIVE at $7.90, LYV at $173.12, PPLI at $40.00). With 2% risk against a 4% target, the effective reward-to-risk is 2:1 on any filled trade. Sizing is fixed-risk at 2% per trade with a 20% cap per position. "Waiting" means setting alerts at $1.70 (HCAT), $7.80 (LIVE), $39.42 (PPLI) and $170 (LYV) and doing nothing until a support tap with a close above prints. One caveat on tuning: no robust parameter setup was established for this rule set — the research author kept the thesis-consistent monitoring posture rather than requesting bounded optimization, so there is no adjusted variant to substitute for the published triggers.

Why the bull case still has support

Of the five tickers attached to this idea, only Health Catalyst (HCAT) actually sells to the health-care theme the thesis gestures at, so the honest bull case is narrow and specific. On the latest fundamentals, HCAT generated $70.5M of revenue in the quarter ended June 30, 2026 and reported positive operating cash flow of $275,000, a notable change given the company ran negative operating cash flow for most of 2020 through 2023. Full-year 2025 revenue of $311.1M against roughly $296M in 2023 shows the top line grinding upward over time, and the last reported annual free cash flow of $9.6M (fiscal Q4 2025) suggests the cash burn problem had at least episodic relief before the Q2 2026 reversal. Insider behavior on HCAT also leans supportive: the ownership panel shows net open-market insider buying of about $105,439 across three reporting holders, with 5.74M shares held as of the June 30, 2026 report period. Insiders buying with their own cash is a modest but real counterweight to a stock that screens badly on margins, because it signals conviction tied to information the public does not yet have. On the data-evidence side, this is a watch-list setup, not an active signal: the rules were evaluated on real daily bars but did not open an entry in the last nine months across 185 evaluated bars, and the research author explicitly retained a thesis-consistent monitoring-only posture rather than loosening the trigger — so zero entries is by design, and no trade is implied today. For the other names, the strongest single numbers are PPLI's 21.8% year-over-year revenue growth and 75.8% gross margin in fiscal Q4 2025, and LOB's consecutive quarterly net income ($30.0M in Q1 2026, rising to $36.8M in Q2 2026) with a stable $0.12 trailing dividend. If you want to defend any part of this basket, it is: one genuine health franchise with insiders buying, one fast-growing digital media operator (People Inc) at the 75th percentile of its sector on revenue growth, and a bank quietly compounding earnings and paying shareholders.

What could break the thesis

Start with the mapping problem: the thesis is about obesity, health obsession, single-person households, and declining births. Four of the five suggested tickers have no plausible connection to those claims. LIVE is a Consumer Discretionary holding company (its latest full fundamentals date to fiscal Q4 2022, per data ending September 30, 2022 — a delayed disclosure, not current), LOB is a bank, LYV is concert promotion, and PPLI is digital media under Barry Diller's IAC umbrella. The basket looks selected on ticker names, not on the thesis. If the demographic claims are right, these companies do not obviously monetize them. The weakest fundamentals sit exactly where the thematic exposure does. HCAT's operating margin in the June 2026 quarter was -51.8%, only marginally improved from -150.5% the quarter before; free cash flow swung from +$18.2M in Q1 2026 to -$70,000 in Q2 2026; full fiscal 2025 net income was -$178.0M including a -$91.0M Q4; and revenue declined 6.2% year over year, sitting at only the 17th percentile of its IT sector. HCAT pays no dividend, so there is no shareholder return cushion while you wait for the health-spend thesis to play out. The insider picture across…

Scores

• Conviction score breakdown: 42
• Thesis support: 25
• Trade readiness: 55
• Risk quality: 45
• Trigger proximity: 50
• Fundamentals trend: 35

Watch items

• HCAT — Daily low vs first support ($1.70)
• HCAT — Daily close vs SMA (50) at $1.84
• LIVE — Daily low vs first support ($7.80)
• PPLI — Daily low vs first support ($39.42)
• LYV — Daily low vs first support ($170.00)
• LOB — Close vs listed first support ($37.47)
• HCAT — Q3 free cash flow (period ending Sep 30, 2026)
• LYV — Next insider ownership filings (September 30 quarter)